Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
Pubmed

Isolation and characterization of retinoic acid-inducible cDNA clones in F9 cells: one of the early inducible clones encodes a novel protein sharing several highly homologous regions with a Drosophila polyhomeotic protein.

RAET1E CD63

3.05e-0612828070621
Pubmed

An antibody-based proximity labeling map reveals mechanisms of SARS-CoV-2 inhibition of antiviral immunity.

SPG11 USP15 TOR1AIP1 ITPR2

1.28e-057338434672954
Pubmed

Amyotrophic Lateral Sclerosis Overview

SPG11 TAF15

2.44e-05338220301623
Pubmed

USP15 Deubiquitinase Safeguards Hematopoiesis and Genome Integrity in Hematopoietic Stem Cells and Leukemia Cells.

TAF15 USP15

2.74e-05358233378683
Pubmed

Identifying biological pathways that underlie primordial short stature using network analysis.

TAF15 MYO5C TOR1AIP1 ITPR2

4.76e-0510248424711643
Pubmed

The interactome of the prostate-specific protein Anoctamin 7.

TAF15 MYO5C

9.56e-05658232176628
Pubmed

C5orf51 is a component of the MON1-CCZ1 complex and controls RAB7A localization and stability during mitophagy.

SPG11 TOR1AIP1 ITPR2

1.60e-045048334432599
Pubmed

Comprehensive interactome profiling of the human Hsp70 network highlights functional differentiation of J domains.

SPG11 TAF15 TOR1AIP1 ITPR2

2.03e-0414878433957083
CytobandEnsembl 112 genes in cytogenetic band chr15q21

SPG11 MYO5C

4.08e-0417782chr15q21
CoexpressionNICK_RESPONSE_TO_PROC_TREATMENT_DN

SPG11 ITPR2

2.85e-052782M8801
CoexpressionZHONG_PFC_MAJOR_TYPES_ASTROCYTES

CD63 TOR1AIP1 ITPR2

1.02e-0432683M39074
CoexpressionLEE_LIVER_CANCER_CIPROFIBRATE_UP

CD63 MYO5C

1.43e-046082M2195
CoexpressionBUSSLINGER_GASTRIC_IMMUNE_CELLS

SPG11 USP15 TOR1AIP1 ITPR2

6.08e-04149284M40023
CoexpressionBASSO_B_LYMPHOCYTE_NETWORK

SPG11 ITPR2

8.44e-0414682M10633
CoexpressionGSE13547_2H_VS_12_H_ANTI_IGM_STIM_ZFX_KO_BCELL_UP

CD63 ITPR2

1.10e-0316782M2995
CoexpressionONDER_CDH1_TARGETS_1_DN

MYO5C TOR1AIP1

1.14e-0317082M6822
CoexpressionGSE9601_UNTREATED_VS_NFKB_INHIBITOR_TREATED_HCMV_INF_MONOCYTE_DN

SPG11 ITPR2

1.20e-0317482M6881
CoexpressionKRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP

SPG11 TAF15 ITPR2

1.30e-0377883M17915
CoexpressionGSE18791_UNSTIM_VS_NEWCATSLE_VIRUS_DC_1H_DN

MYO5C TOR1AIP1

1.47e-0319382M4286
CoexpressionGSE22886_NAIVE_CD8_TCELL_VS_NKCELL_DN

TAF15 CD63

1.53e-0319782M4421
CoexpressionGSE36888_STAT5_AB_KNOCKIN_VS_WT_TCELL_IL2_TREATED_17H_DN

USP15 ITPR2

1.53e-0319782M8755
CoexpressionGSE3982_EFF_MEMORY_VS_CENT_MEMORY_CD4_TCELL_DN

USP15 MYO5C

1.54e-0319882M5571
CoexpressionGSE13484_12H_UNSTIM_VS_YF17D_VACCINE_STIM_PBMC_DN

USP15 MYO5C

1.54e-0319882M3273
CoexpressionGSE9509_LPS_VS_LPS_AND_IL10_STIM_IL10_KO_MACROPHAGE_10MIN_UP

MYO5C TOR1AIP1

1.56e-0319982M6895
CoexpressionGSE369_SOCS3_KO_VS_IFNG_KO_LIVER_UP

SPG11 ITPR2

1.56e-0319982M5978
CoexpressionGSE23502_WT_VS_HDC_KO_MYELOID_DERIVED_SUPPRESSOR_CELL_COLON_TUMOR_DN

MYO5C TOR1AIP1

1.56e-0319982M8086
CoexpressionGSE24142_EARLY_THYMIC_PROGENITOR_VS_DN3_THYMOCYTE_FETAL_DN

SPG11 ITPR2

1.56e-0319982M4571
CoexpressionGSE3720_VD1_VS_VD2_GAMMADELTA_TCELL_WITH_PMA_STIM_DN

SPG11 ITPR2

1.57e-0320082M6360
CoexpressionGSE4142_PLASMA_CELL_VS_GC_BCELL_UP

TAF15 TOR1AIP1

1.57e-0320082M6390
CoexpressionGSE14308_INDUCED_VS_NATURAL_TREG_DN

TAF15 ITPR2

1.57e-0320082M3399
CoexpressionGSE18893_CTRL_VS_TNF_TREATED_TREG_2H_DN

SPG11 ITPR2

1.57e-0320082M7303
CoexpressionGSE32986_CURDLAN_LOWDOSE_VS_GMCSF_AND_CURDLAN_LOWDOSE_STIM_DC_UP

SPG11 ITPR2

1.57e-0320082M8625
CoexpressionGSE26343_WT_VS_NFAT5_KO_MACROPHAGE_LPS_STIM_DN

USP15 ITPR2

1.57e-0320082M8651
CoexpressionGSE4748_CTRL_VS_CYANOBACTERIUM_LPSLIKE_STIM_DC_3H_UP

SPG11 TAF15

1.57e-0320082M6477
CoexpressionGSE25085_FETAL_LIVER_VS_FETAL_BM_SP4_THYMIC_IMPLANT_UP

SPG11 USP15

1.57e-0320082M8075
CoexpressionGSE360_L_DONOVANI_VS_L_MAJOR_MAC_UP

TAF15 TOR1AIP1

1.57e-0320082M5231
CoexpressionGSE27786_LSK_VS_MONO_MAC_DN

USP15 ITPR2

1.57e-0320082M4765
CoexpressionGSE27786_LIN_NEG_VS_MONO_MAC_UP

USP15 MYO5C

1.57e-0320082M4796
CoexpressionDACOSTA_UV_RESPONSE_VIA_ERCC3_DN

SPG11 TAF15 USP15

1.72e-0385683M4500
CoexpressionACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_UP

MYO5C TOR1AIP1 ITPR2

1.76e-0386383M4950
ToppCell367C-Lymphocytic-CD4_T-cell-Treg_cell_2|CD4_T-cell / Donor, Lineage, Cell class and subclass (all cells)

USP15 MYO5C

3.22e-04154829200e2f1783e54cbc5dfc3b485b57c761af74a46
ToppCellileum-BEST4+_Enterocytes|ileum / shred on tissue and cell subclass

MYO5C ITPR2

3.22e-0415482608e9c982125e0c2c15b86b1920813845a0db81f
ToppCellfacs-Marrow-T-cells-24m-Myeloid-granulocyte_monocyte_progenitor_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RAET1E CD63

3.87e-04169821558606be0a8bcd4fd0ce609701a1411e4ca2f9f
ToppCellIIF-Lymphocyte-T_NK-Treg|IIF / Disease, Lineage and Cell Type

USP15 MYO5C

3.87e-0416982aac6ff89e0b3bc1f644e6cc6a696360659b254b5
ToppCellfacs-Marrow-T-cells-24m-Myeloid-granulocyte_monocyte_progenitor_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RAET1E CD63

3.87e-04169821b2354de1ce4080118d9f01e7c5fd6079e705125
ToppCell10x3'2.3-week_14-16-Hematopoietic-HSC/MPP_and_pro-eo/baso/mast_precursor|week_14-16 / cell types per 3 fetal stages;per 3',per 5'

CD63 ITPR2

4.01e-04172827fb43b3938b9a3b6935ec22d9d853e7d47b82b3c
ToppCell367C-Fibroblasts-Fibroblast-J_(Lipofibroblast)-|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)

RAET1E MYO5C

4.05e-04173823aa90578371039f81b7c6fa873ec70f8f2bc7dfa
ToppCell367C-Fibroblasts-Fibroblast-J_(Lipofibroblast)|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)

RAET1E MYO5C

4.05e-04173823d7c281a1a9f183a5a861d1a9c7b50d216535893
ToppCellsevere_COVID-19-HSPC|severe_COVID-19 / disease group, cell group and cell class (v2)

RAET1E MYO5C

4.10e-04174826d35bacf073537b272ff821e604c899fb9ce6a7c
ToppCelldroplet-Lung-18m-Hematologic-myeloid-classical_monocyte_proliferating-classical_monocyte_proliferating_l2|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

RAET1E SPG11

4.20e-04176821510cdfcfb46ce1196a1220c07fb5f3986c81b78
ToppCellsevere_COVID-19-HSPC|World / disease group, cell group and cell class (v2)

RAET1E MYO5C

4.24e-0417782289f6aed6f054b04b01659434d8c8b467d1bf5dd
ToppCelldroplet-Lung-3m-Epithelial-alveolar_epithelial-type_I_pneumocyte-type_1_alveolar_epithelial_cell|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

RAET1E MYO5C

4.34e-0417982ca70a5518c5a5392e088c103e0cb44aa084f5332
ToppCell3'-Adult-LargeIntestine-Epithelial-Tuft-related-Tuft|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract

RAET1E ITPR2

4.34e-0417982906555ce2ca264a0215b120c7ff7c9b411de6a34
ToppCelldroplet-Lung-3m-Epithelial-alveolar_epithelial-type_I_pneumocyte|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

RAET1E MYO5C

4.34e-0417982c451b074b04eb5d6c575c6abaedda579c6744bbf
ToppCellTCGA-Pancreas-Primary_Tumor-Pancreatic_Adenocarcinoma-Ductal_Adenocarcinoma-4|TCGA-Pancreas / Sample_Type by Project: Shred V9

TOR1AIP1 ITPR2

4.58e-041848267164bb6bcae7322cb89b585c7aa10bce35b0ecd
ToppCellfacs-Lung-EPCAM-3m|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CD63 MYO5C

4.68e-04186827c4eb769574f9f32753cea1cc38c711dabba88b9
ToppCell343B-Myeloid-Macrophage-M2-like_Macrophage_(MARCO_negative)|Myeloid / Donor, Lineage, Cell class and subclass (all cells)

CD63 ITPR2

4.68e-04186829673367cb53bafb873a01ef6bda11d9f392ce648
ToppCellILEUM-inflamed-(3)_MNP-(3)_moDC|(3)_MNP / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)

USP15 ITPR2

4.73e-04187820099def970fbc828756fbf853eca2ce77b8cd342
ToppCellVE-Treg|VE / Condition, Cell_class and T cell subcluster

USP15 MYO5C

4.78e-0418882ef048517dfe2fc995d13eb1f08106a487354a4cc
ToppCellVE-Treg-CD4_Treg|VE / Condition, Cell_class and T cell subcluster

USP15 MYO5C

4.78e-0418882fa88ceb336e30de3585e62608527a0d44df74190
ToppCellNon-neuronal-Non-dividing-OPC|World / Primary Cells by Cluster

CD63 ITPR2

4.83e-041898213848a031ab896b4b24c8319e4745b9b17ff9cfd
ToppCellNon-neuronal-Non-dividing-OPC-OPC|World / Primary Cells by Cluster

CD63 ITPR2

4.83e-0418982ddf5be73912570c32c50f4ac2902da9b590526f8
ToppCellNon-neuronal-Non-dividing-OPC-OPC-30|World / Primary Cells by Cluster

CD63 ITPR2

4.83e-0418982313d165fad541ec6e8dd524b88856e2c93eeb681
ToppCell356C-Myeloid-Macrophage-M2-like_Macrophage_(MARCO_negative)|Myeloid / Donor, Lineage, Cell class and subclass (all cells)

CD63 ITPR2

4.89e-0419082d541e076137cf7334bdb0ed69db2f9a27c668c65
ToppCell10x_3'_v3-lymph_node_(10x_3'_v3)-lymphocytic-T_lymphocytic-regulatory_T_cell|lymph_node_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type

USP15 MYO5C

4.89e-0419082b69709323a9f1b368b5a4f87295b9f7fd9c9be8e
ToppCellE18.5-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

CD63 MYO5C

4.94e-041918208b1d3b3be78bf7fd9e9039027e35275f2be88d0
ToppCellE18.5-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2-AT2_mature|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

CD63 MYO5C

4.94e-0419182f896fb490c4a17adac5e00ed9b6e6145eab1e564
ToppCellPND28-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2-AT2_mature|PND28 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

CD63 MYO5C

4.99e-04192827ccdb977320d09f21e70e7718ead73eeb56d0c48
ToppCellPND28-Epithelial-Epithelial_Alveolar|PND28 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

CD63 MYO5C

4.99e-041928269963e8dc6d6368243e61da133484eb23225625a
ToppCellPND28-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2|PND28 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

CD63 MYO5C

4.99e-0419282bfc68af68fdb99ddfe4add49671e4b4c26e6f962
ToppCellPND28-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar|PND28 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

CD63 MYO5C

4.99e-0419282f206c015f091234e2c86dfa66926e97b2ea99690
ToppCell10x_5'_v1-Non-neoplastic-Lymphoid-CD4/CD8-Reg_T-F_2|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

USP15 MYO5C

5.25e-041978254fb7197db3c0dc87a1114e1ab1d2bfafd564b35
ToppCell10x_5'_v1-Non-neoplastic-Lymphoid-CD4/CD8-Reg_T|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

USP15 MYO5C

5.30e-041988203423d6c614440b9c738f75ac3f5a6941719a279
ToppCellSigmoid-T_cell-Treg|T_cell / Region, Cell class and subclass

USP15 MYO5C

5.30e-0419882e2d2f9f209f77d0c48cfe3e9902c0ae0795511b2
ToppCellMS-IIF-Lymphocyte-T/NK-Treg|IIF / Disease, condition lineage and cell class

USP15 MYO5C

5.30e-04198827bbf8403ecf9f8e403b04f18d265ece977cc49e7
ToppCellmLN-Macrophage-LYVE1_Macrophage|Macrophage / Region, Cell class and subclass

SPG11 USP15

5.41e-0420082e3c15e0e1c2602b0cc9ab8cc50c978d265350c94
ToppCellCOVID-19-Myeloid-MoAM2,_CCL18|COVID-19 / Condition, Lineage and Cell class

CD63 ITPR2

5.41e-0420082b0a50622d00335843efad86bc56a1e910019984b
ToppCellBrain_organoid-organoid_Tanaka_cellReport-6m|organoid_Tanaka_cellReport / Sample Type, Dataset, Time_group, and Cell type.

CD63 ITPR2

5.41e-04200825ba4ed490c64b3bb738e7729669f893fa73aa56f
DrugAsiaticoside [16830-15-2]; Up 200; 4.2uM; PC3; HT_HG-U133A

TAF15 USP15 ITPR2

3.46e-05197837244_UP
Drugfluphenazine dihydrochloride; Down 200; 10uM; MCF7; HT_HG-U133A_EA

TAF15 TOR1AIP1 ITPR2

3.46e-05197831017_DN
DrugAdamantamine fumarate [80789-67-9]; Down 200; 9.6uM; HL60; HT_HG-U133A

MYO5C TOR1AIP1

1.76e-03184821344_DN
Drug5707885; Up 200; 50uM; PC3; HT_HG-U133A

TAF15 ITPR2

1.80e-03186826438_UP
DrugMethotrimeprazine maleat salt [7104-38-3]; Up 200; 9uM; PC3; HT_HG-U133A

TOR1AIP1 ITPR2

1.84e-03188823701_UP
DrugAmitryptiline hydrochloride [549-18-8]; Down 200; 12.8uM; HL60; HT_HG-U133A

MYO5C ITPR2

1.84e-03188821865_DN
Drug0297417-0002B [362658-29-5]; Up 200; 10uM; PC3; HT_HG-U133A

TOR1AIP1 ITPR2

1.86e-03189826895_UP
DrugSeneciphylline [480-81-9]; Down 200; 12uM; MCF7; HT_HG-U133A

TAF15 ITPR2

1.86e-03189822797_DN
DrugSelegiline hydrochloride [14611-52-0]; Down 200; 17.8uM; HL60; HT_HG-U133A

TAF15 ITPR2

1.88e-03190822465_DN
DrugRapamycin; Down 200; 0.1uM; MCF7; HT_HG-U133A

TAF15 ITPR2

1.88e-03190821632_DN
DrugFlunisolide [3385-03-3]; Down 200; 9.2uM; PC3; HT_HG-U133A

TAF15 TOR1AIP1

1.90e-03191824303_DN
DrugBenfluorex hydrochloride [23642-66-2]; Down 200; 10.4uM; HL60; HT_HG-U133A

TAF15 TOR1AIP1

1.92e-03192821266_DN
DrugEthopropazine hydrochloride [1094-08-2]; Down 200; 11.4uM; PC3; HT_HG-U133A

TAF15 ITPR2

1.94e-03193826697_DN
Drugikarugamycin; Down 200; 2uM; MCF7; HT_HG-U133A_EA

TAF15 ITPR2

1.94e-0319382974_DN
DrugIsocarboxazid [59-63-2]; Up 200; 17.2uM; PC3; HT_HG-U133A

TAF15 ITPR2

1.94e-03193823684_UP
DrugCeforanide [60925-61-3]; Down 200; 7.6uM; PC3; HT_HG-U133A

TOR1AIP1 ITPR2

1.94e-03193826751_DN
DrugHycanthone [3105-97-3]; Down 200; 11.2uM; PC3; HT_HG-U133A

TAF15 ITPR2

1.94e-03193824630_DN
DrugCarbetapentane citrate [23142-01-0]; Down 200; 7.6uM; HL60; HT_HG-U133A

MYO5C TOR1AIP1

1.94e-03193821268_DN
DrugPF-00539758-00 [351321-34-1]; Up 200; 10uM; PC3; HT_HG-U133A

USP15 TOR1AIP1

1.94e-03193826421_UP
DrugFlumethasone [2135-17-3]; Down 200; 9.8uM; PC3; HT_HG-U133A

TAF15 ITPR2

1.96e-03194824272_DN
DrugChlortetracycline hydrochloride [64-72-2]; Down 200; 7.8uM; PC3; HT_HG-U133A

TAF15 TOR1AIP1

1.96e-03194826761_DN
DrugMorantel tartrate [26155-31-7]; Down 200; 10.8uM; HL60; HT_HG-U133A

TAF15 TOR1AIP1

1.96e-03194821840_DN
DrugBetazole hydrochloride; Up 200; 27uM; PC3; HT_HG-U133A

TAF15 TOR1AIP1

1.96e-03194821812_UP
DrugEquilin [474-86-2]; Down 200; 15uM; MCF7; HT_HG-U133A

TAF15 ITPR2

1.96e-03194825620_DN
DrugNifedipine [21829-25-4]; Down 200; 11.6uM; HL60; HT_HG-U133A

TOR1AIP1 ITPR2

1.96e-03194821856_DN
DrugPHA-00846566E [724718-26-7]; Up 200; 10uM; PC3; HT_HG-U133A

USP15 ITPR2

1.96e-03194827086_UP
DrugFenbufen [36330-85-5]; Down 200; 15.8uM; PC3; HT_HG-U133A

TOR1AIP1 ITPR2

1.98e-03195823721_DN
DrugCloperastine hydrochloride [14984-68-0]; Down 200; 11uM; PC3; HT_HG-U133A

USP15 TOR1AIP1

1.98e-03195823710_DN
DrugThiamphenicol [15318-45-3]; Down 200; 11.2uM; HL60; HT_HG-U133A

TAF15 MYO5C

1.98e-03195821867_DN
Drugtrifluoperazine dihydrochloride; Down 200; 10uM; MCF7; HT_HG-U133A_EA

USP15 ITPR2

1.98e-0319582910_DN
DrugBumetanide [28395-03-1]; Down 200; 11uM; HL60; HT_HG-U133A

MYO5C ITPR2

1.98e-03195822409_DN
DrugTyloxapol [25301-02-4]; Down 200; 4uM; PC3; HT_HG-U133A

TAF15 TOR1AIP1

1.98e-03195824611_DN
DrugF0447-0125; Down 200; 10uM; MCF7; HT_HG-U133A

TAF15 ITPR2

1.98e-03195826424_DN
DrugAdiphenine hydrochloride [50-42-0]; Up 200; 11.4uM; PC3; HT_HG-U133A

TAF15 ITPR2

1.98e-03195821831_UP
Drugyohimbine; Down 200; 22.9uM; MCF7; HT_HG-U133A_EA

TAF15 TOR1AIP1

1.98e-03195821119_DN
DrugIsoconazole [27523-40-6]; Down 200; 9.6uM; PC3; HT_HG-U133A

TAF15 TOR1AIP1

1.98e-03195825857_DN
DrugZalcitabine [7481-89-2]; Up 200; 19uM; MCF7; HT_HG-U133A

TOR1AIP1 ITPR2

1.98e-03195824799_UP
DrugDipyridamole [58-32-2]; Down 200; 8uM; PC3; HG-U133A

SPG11 USP15

1.98e-03195821934_DN
DrugDiclofenac sodium [15307-79-6]; Down 200; 12.6uM; PC3; HT_HG-U133A

TAF15 TOR1AIP1

2.00e-03196825861_DN
DrugBenzonatate [104-31-4]; Up 200; 6.6uM; PC3; HT_HG-U133A

TOR1AIP1 ITPR2

2.00e-03196821801_UP
DrugZimelidine dihydrochloride monohydrate [61129-30-4]; Down 200; 9.8uM; MCF7; HT_HG-U133A

TOR1AIP1 ITPR2

2.00e-03196821512_DN
DrugMidecamycin [35457-80-8]; Down 200; 5uM; PC3; HT_HG-U133A

TOR1AIP1 ITPR2

2.00e-03196826745_DN
DrugChlorpromazine hydrochloride [69-09-0]; Down 200; 11.2uM; HL60; HT_HG-U133A

TAF15 ITPR2

2.00e-03196821864_DN
Drug3-Acetylcoumarin [3949-36-8]; Down 200; 21.2uM; MCF7; HT_HG-U133A

TAF15 ITPR2

2.00e-03196825624_DN
DrugMoricizine hydrochloride [31883-05-3]; Down 200; 8.6uM; PC3; HT_HG-U133A

USP15 ITPR2

2.00e-03196827297_DN
DrugCarisoprodol [78-44-4]; Down 200; 15.4uM; MCF7; HT_HG-U133A

TAF15 ITPR2

2.00e-03196824955_DN
DrugHydrastinine hydrochloride [4884-68-8]; Down 200; 16.4uM; PC3; HT_HG-U133A

USP15 TOR1AIP1

2.00e-03196822119_DN
DrugLY 294002; Down 200; 0.1uM; PC3; HT_HG-U133A

TOR1AIP1 ITPR2

2.00e-03196821216_DN
DrugCinchonine [118-10-5]; Down 200; 13.6uM; HL60; HT_HG-U133A

TAF15 ITPR2

2.02e-03197822133_DN
DrugHomosalate [118-56-9]; Down 200; 15.2uM; PC3; HT_HG-U133A

TOR1AIP1 ITPR2

2.02e-03197823797_DN
DrugPantothenic acid calcium salt monohydrate [63409-48-3]; Down 200; 8uM; HL60; HT_HG-U133A

TAF15 TOR1AIP1

2.02e-03197821311_DN
DrugReserpinic acid hydrochloride; Down 200; 9.2uM; HL60; HT_HG-U133A

MYO5C ITPR2

2.02e-03197822903_DN
DrugSR-95639A [115767-94-7]; Down 200; 10uM; MCF7; HT_HG-U133A

TAF15 ITPR2

2.02e-03197824977_DN
DrugPhenindione [83-12-5]; Up 200; 18uM; PC3; HT_HG-U133A

TAF15 ITPR2

2.02e-03197827289_UP
DrugIfosfamide [3778-73-2]; Down 200; 15.4uM; PC3; HT_HG-U133A

TAF15 TOR1AIP1

2.02e-03197825805_DN
DrugLomefloxacin hydrochloride [98079-52-8]; Down 200; 10.4uM; PC3; HT_HG-U133A

TOR1AIP1 ITPR2

2.02e-03197823723_DN
DrugHomatropine hydrobromide (R,S) [51-56-9]; Down 200; 11.2uM; HL60; HT_HG-U133A

TAF15 MYO5C

2.02e-03197821848_DN
DrugMedrysone [2668-66-8]; Down 200; 11.6uM; HL60; HT_HG-U133A

TAF15 TOR1AIP1

2.02e-03197822544_DN
DrugBenzthiazide [91-33-8]; Down 200; 9.2uM; PC3; HT_HG-U133A

TAF15 TOR1AIP1

2.02e-03197826607_DN
DrugClebopride maleate [84370-95-6]; Down 200; 8.2uM; MCF7; HT_HG-U133A

TAF15 ITPR2

2.02e-03197822646_DN
DrugApomorphine hydrochloride hemihydrate [41372-20-7]; Down 200; 6.4uM; PC3; HT_HG-U133A

TAF15 ITPR2

2.02e-03197826683_DN
DrugTriamterene [396-01-0]; Up 200; 15.8uM; HL60; HT_HG-U133A

TAF15 ITPR2

2.04e-03198821861_UP
DrugBetonicine [515-25-3]; Up 200; 25.2uM; PC3; HT_HG-U133A

TOR1AIP1 ITPR2

2.04e-03198824301_UP
DrugRanitidine hydrochloride [66357-59-3]; Down 200; 11.4uM; HL60; HG-U133A

SPG11 TOR1AIP1

2.04e-03198821404_DN
DrugPhenylpropanolamine hydrochloride [154-41-6]; Down 200; 21.4uM; MCF7; HT_HG-U133A

TAF15 TOR1AIP1

2.04e-03198825298_DN
DrugPepstatin A [26305-03-3]; Down 200; 5.8uM; HL60; HT_HG-U133A

TAF15 MYO5C

2.04e-03198821328_DN
DrugAcenocoumarol [152-72-7]; Down 200; 11.4uM; PC3; HT_HG-U133A

TAF15 TOR1AIP1

2.04e-03198825878_DN
DrugNS-398; Up 200; 10uM; PC3; HT_HG-U133A

TOR1AIP1 ITPR2

2.04e-03198826892_UP
DrugFuraltadone hydrochloride [3759-92-0]; Down 200; 11uM; PC3; HT_HG-U133A

TAF15 ITPR2

2.04e-03198823756_DN
DrugSeneciphylline [480-81-9]; Down 200; 12uM; HL60; HT_HG-U133A

TAF15 ITPR2

2.04e-03198822140_DN
Drugbeta- Belladonnine dichloroethylate [191355-47-2]; Down 200; 6uM; HL60; HT_HG-U133A

TAF15 ITPR2

2.04e-03198822164_DN
Drugbenserazide hydrochloride; Up 200; 10uM; SKMEL5; HG-U133A

SPG11 USP15

2.04e-0319882631_UP
DrugSulfabenzamide [127-71-9]; Down 200; 14.4uM; HL60; HT_HG-U133A

TAF15 ITPR2

2.04e-03198822159_DN
DrugAld1.1-H_000455; Down 200; 10uM; MCF7; HT_HG-U133A

USP15 ITPR2

2.04e-03198827516_DN
DrugBemegride [64-65-3]; Up 200; 25.8uM; MCF7; HT_HG-U133A

TAF15 ITPR2

2.06e-03199823389_UP
DrugMilrinone [78415-72-2]; Down 200; 19uM; PC3; HT_HG-U133A

TAF15 TOR1AIP1

2.06e-03199825856_DN
DrugPerphenazine [58-39-9]; Down 200; 10uM; PC3; HT_HG-U133A

TAF15 ITPR2

2.06e-03199824637_DN
DrugStreptozotocin [18883-66-4]; Up 200; 15uM; HL60; HT_HG-U133A

TAF15 TOR1AIP1

2.06e-03199822535_UP
DrugMafenide hydrochloride [138-37-4]; Down 200; 18uM; MCF7; HT_HG-U133A

TAF15 ITPR2

2.06e-03199822287_DN
Drughaloperidol; Up 200; 10uM; HL60; HT_HG-U133A

TAF15 MYO5C

2.06e-03199821185_UP
DrugScopolamine hydrochloride [55-16-3]; Down 200; 11.8uM; MCF7; HT_HG-U133A

TOR1AIP1 ITPR2

2.06e-03199823357_DN
DrugS(-)Eticlopride hydrochloride [97612-24-3]; Down 200; 10.6uM; PC3; HT_HG-U133A

TAF15 ITPR2

2.06e-03199824634_DN
DrugAtractyloside potassium salt [102130-43-8]; Up 200; 5uM; HL60; HT_HG-U133A

TOR1AIP1 ITPR2

2.08e-03200822573_UP
DrugFlucytosine [2022-85-7]; Down 200; 31uM; PC3; HT_HG-U133A

TAF15 ITPR2

2.08e-03200826690_DN
DrugSulfamethoxazole [723-46-6]; Up 200; 15.8uM; PC3; HT_HG-U133A

TAF15 ITPR2

2.08e-03200823667_UP
DrugNadide [53-84-9]; Down 200; 6uM; PC3; HT_HG-U133A

TAF15 TOR1AIP1

2.08e-03200825873_DN
DiseaseAbnormality of refraction

TOR1AIP1 ITPR2

1.33e-0267382HP_0000539
Diseaseplatelet crit

USP15 ITPR2

2.56e-0295282EFO_0007985

Protein segments in the cluster

PeptideGeneStartEntry
LNKNLFLQYNSDNNM

RAET1E

56

Q8TD07
GNMNFARRNSCNQCN

TAF15

366

Q92804
LQNFLRNQNNKTNYN

ITPR2

1936

Q14571
NNNFRQQMENYPKNN

CD63

116

P08962
NQNTSCNNYMRNEIL

SPG11

926

Q96JI7
QEFQNQMNQLKNKYQ

TOR1AIP1

366

Q5JTV8
LSNNYNNMNNRNVKN

USP15

246

Q9Y4E8
NNMNNRNVKNSNYCL

USP15

251

Q9Y4E8
CINYANEKLQQQFNM

MYO5C

451

Q9NQX4